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Next to selfishness, the principal cause that makes life unsatisfactory is lack of mental 
cultivation. John Stuart Mill (Utilitarianism 1861) 
  
 
 
 
 
  
ABSTRACT 
Although Sudden Unexpected Death in Epilepsy (SUDEP) has attracted increasing 
attention from the scientific community during the last 20 years, important gaps in 
knowledge still exist that hamper the development of methods aiming at prevention of this, 
the most devastating consequence of epilepsy. We are still missing large population-based 
studies on the incidence of SUDEP. Our understanding of the circumstances surrounding 
SUDEP is incomplete which is a major limitation when it comes to development of 
potential SUDEP-preventing devices. Finally, our understanding of risk factors for SUDEP 
is limited to a few established risk factors. The purpose of this study was to examine the 
incidence, circumstances and risk factors for SUDEP in Sweden. 
 
The project is based on a study population (n=78 524) which comprises all persons living in 
Sweden at 1. July 2006, who at some point during 1998-2005 where registered with the 
diagnosis code for epilepsy (ICD G 40) in the Swedish National Patient Register (SNPR). 
To identify cases of SUDEP, the study population was linked to the National Cause-of-
Death Register. During the follow-up time from July 1, 2006 to December 31, 2011, we 
identified 9605 deaths. All death certificates in the study population between 1 July 2006 
and 31 December 2011 with epilepsy mentioned on death certificate and all deaths during 
2008 (n=3166) were reviewed. Based on the information in the death certificates, obvious 
non-SUDEP deaths were excluded from further analysis. For all others we analyzed patient 
medical records, autopsy and police reports and information was extracted using a 
standardized protocol. From the study population, five epilepsy controls per SUDEP case, 
of the same sex, who were alive at the case´s time of death, were randomly selected by the 
National Board of Health and Welfare.  
 
During 2008, 1890 individuals from the study population died. Of these, 99 met Annegers‘ 
SUDEP criteria (49 definite, 19 probable, and 31 possible) (paper I). Definite and probable 
SUDEP accounted for 3.6% of all deaths in the study population during 2008, and 5.2% 
when possible was included. In the age group 0-15 years, the relative contribution of 
SUDEP (definite, probable and possible) to overall deaths was 36.0%. SUDEP incidence 
was 1.20/1000 person-years (definite/ probable) and 1.74/1000 if possible SUDEP was 
included. Epilepsy was mentioned in any position of the death certificate in 63.6% of the 99 
SUDEP cases. 
 
Of the 329 SUDEP deaths identified from July 1, 2006 to December 31, 2011 (167 definite, 
89 probable, 73 possible), more than half (58%) occurred at night and 91% died at home, 
whereof 65% were found deceased in bed (paper II). Death was witnessed in 17% of all 
SUDEP cases and when a seizure was witnessed in conjunction with SUDEP (n=49) all 
were generalized tonic-clonic seizures (GTCS). Where a body position was documented 
(43%), more than two thirds (70%) were found prone. Dying at night made it more likely 
(80%) to be found prone than other times (55%) (p<0.001). Among adult SUDEP cases, 
75% were living alone, and only 14% of all SUDEP cases shared a bedroom.  
 
In papers III and IV, 255 SUDEP cases (167 definite, 88 probable) were compared to their 
matched 1148 controls. Those with a history of GTCS had a tenfold increased SUDEP risk 
and the risk was increased to 32-fold with 4-10 GTCS during the last year of observation. 
When a history of nocturnal GTCS was present, a nine-fold SUDEP risk was observed and 
a 15-fold risk was seen if nocturnal GTCS were present during the last year of observation. 
No increased risk of SUDEP was seen in those experiencing exclusively non-GTCS during 
the preceding year. There was a fivefold increased risk of SUDEP among those living 
alone, while the risk was reduced to twofold when sharing household but not bedroom. 
Individuals experiencing ≥1 GTCS and not sharing a bedroom with someone had 67-fold 
increased risk of SUDEP compared to individuals not having GTCS, who shared their 
bedroom with someone, with attributable proportion due to interaction estimated at 0.69 
(95% confidence interval, CI 0.53-0.85). Polytherapy, especially taking three or more 
AEDs was associated with a 69% reduced SUDEP risk after adjusting for GTCS frequency 
and other covariates. Levetiracetam as monotherapy was associated with a significantly 
lower SUDEP risk when compared to no AED treatment (odds ratio, OR 0.10, 95% CI 
0.03-0.61). Lamotrigine, valproic acid and levetiracetam were associated with a 
significantly reduced risk when used as part of a polytherapy. Use of statins was associated 
with a reduced risk of SUDEP (OR 0.34, 95% CI 0.11-0.99). 
 
Our results show that SUDEP is an important contributor to mortality in epilepsy patients, 
and accounts for one third of deaths in children with epilepsy and one fifth of deaths among 
young adults with epilepsy. Since the majority died at home in bed, at night with 
indications of a previous GTCS, SUDEP can be considered an event related to night time 
and unobserved GTCS. We found no excess risk of SUDEP among individuals 
experiencing non-GTCS only, which has important clinical implications. GTCS and lack of 
supervision were the main risk factors. Moreover, our results suggest that up to 69% of 
SUDEP cases could be prevented in individuals with GTCS who live alone, if they were 
made free from GTCS or did not sleep alone. Polytherapy was associated with a 
substantially reduced SUDEP risk indicating that physicians should to consider AED 
polytherapy more pro-actively for patients with poorly controlled GTCS.   
 
  
SAMMANFATTNING PÅ SVENSKA  
Epilepsi är det vanligaste allvarliga kroniska neurologiska sjukdomstillståndet med en 
prevalens på 6- 7/1 000. Epilepsi kan ha allvarliga konsekvenser. Av särskild vikt är 
förhöjd mortalitet, 2 – 3 gånger högre än förväntat och därav påtagligt förkortad livslängd. 
Den förhöjda mortaliteten förklaras delvis av underliggande orsaker till epilepsi såsom 
hjärntumörer och cerebrovaskulär sjukdom men är också delvis en konsekvens av 
anfallssjukdomen. Plötslig oväntad död, sudden unexpected death in epilepsy (SUDEP), 
anses vara den främsta epilepsirelaterade dödsorsaken. Plötslig död är 20 gånger vanligare 
hos personer med epilepsi jämfört med befolkningen i allmänhet. Även om SUDEP har fått 
ökad uppmärksamhet under de senaste 20 åren, finns det fortfarande stora kunskapsluckor. 
Syftet med avhandlingen har varit att ta fram ny kunskap om förekomst, riskfaktorer och 
omständigheter runt SUDEP, med det övergripande målet att skapa bättre underlag för 
framtida åtgärder för att förhindra denna förödande konsekvens av epilepsi.  
 
Målet med delarbete I var att identifiera alla fall av SUDEP i Sverige under ett år. Vi 
inkluderade alla individer med epilepsidiagnos i svenska patentregistret under 1998–2005 
och som var vid liv den första januari 2008. Av dessa 57 775 personer hade 1890 (3,3%) 
avlidit under 2008. 99 uppfylllde kriterierna för SUDEP som stod för 5,2% av alla dödsfall 
bland personer med epilepsi och 36% av dödsfallen i åldersgruppen 0-15 år. Förekomsten 
av s.k. definite/probable SUDEP var 1,20/1000 personår, vilket är i linje med tidigare 
rapporeer. Att risken var ungefär lika stor bland barn som bland vuxna är emellertid en ny 
observation. Epilepsi nämndes någonstans på dödsorsaksintyget hos 64% av all SUDEP-
fall. Sammanfattningsvis visade studien att SUDEP står för en betydande andel av alla 
dödsfall hos epilepsipatienter och dödsorsaksintyg inte är en tillräckligt känslig metod för 
att upptäcka SUDEP fall.  
 
Syftet med delarbete II var att analysera omständigheterna kring SUDEP. 
Studiepopulationen bestod av alla individer med epilepsidiagnos i det svenska 
patientregistret från 1998–2005, som var vid liv den 30 juni 2006 (n = 60 952). Vi 
identifierade 329 SUDEP fall under uppföljningsperioden 1 juli 2006 t.o.m. 31 december 
2011. Hos 17% var dödsfallet bevittnat och hos 88% av dessa observerades ett epileptiskt 
anfall i samband med dödsfallet, alla dessa hade ett generaliserat tonisk-kloniskt anfall. De 
flesta SUDEP-fallen bodde ensamma och endast 14% delade sovrum. Jämfört med en 
referensgrupp bestående av personer med epilepsi som avlidit av andra fastställda orsaker 
än SUDEP, avled de s.k. definite SUDEP oftare hemma, under natten, obevittnade, och 
hittades oftare liggande på magen. De var också vanligare att SUDEP-fallen var 
ensamboende och att de uppvisade tecken på föregående anfall. Observationerna indikerar 
att brist på tillsyn är en vanlig omständighet vid SUDEP och detta bör beaktas vid 
utveckling av förebyggande strategier. 
 
I delarbete III genomförde vi en landsomfattande fallkontrollstudie för att testa hypotesen 
att vissa specifika kliniska riskfaktorer är förknippade med ökad risk för SUDEP. Studien 
inkluderade 255 SUDEP-fall (definite och probable) och 1148 matchade kontroller, 
epilepsipatienter som inte avlidit. Studien visade att förekomst av generaliserade tonisk-
kloniska anfall (GTCS) under året före döden var förknippat med en 27-faldigt ökad 
SUDEP risk. Ingen ökad risk observerades hos personer med epileptiska anfall som inte var 
av typen GTCS. Nattliga GTCS under observationsåret var förknippade med en 15-faldig 
riskökning och att leva ensam var associerat med en femfaldigt ökad risk för SUDEP. 
Interaktionsanalys visade att kombinationen av att inte dela sovrum och att ha GTCS var 
förenat med en 67-faldigt ökad risk för SUDEP. Resultaten indikerar att 69% av SUDEP-
fall som har GTCS och bor ensamma skulle kunna förhindras om de inte var obevakade på 
natten eller var fria från GTCS. 
 
I delarbete IV användes samma fall och kontroller som i arbete III för att studera sambandet 
mellan användning av antiepileptika (AEDs), och andra potentiellt relevanta läkemedel och 
SUDEP-risk. Polyterapi (minst två AED givna i kombination) var associerad med en 
minskad risk för SUDEP, även efter justering för anfall, levnadsvanor och ett stort antal 
andra möjliga riskfaktorer. Inget AED, vare sig i mono- eller polyterapi, var associerat till 
ökad risk för SUDEP. Levetiracetam var den enda monoterapin som var associerad med en 
statisitiskt signifikant reducerad SUDEP-risk. Vi observerade ingen ökad eller minskad risk 
för SUDEP i samband med behandling med SSRI, andra antidepressiva, neuroleptika eller 
beta-blockerare. Däremot fanns en minskad risk för SUDEP bland personer som använde 
statiner. Våra resultat tyder på att AEDs kan ha en skyddande effekt utöver de 
anfallskontrollerande egenskaperna.  
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1 INTRODUCTION 
Epilepsy is among the oldest recognized diseases and narrations date back to Mesopotamian 
writings (Kinnear 1990). The word, epilepsy, derives from the Greek meaning ‘’to take 
hold’’.  Epilepsy is one of the most common serious chronic neurological conditions with a 
prevalence of 0.6-0.7% affecting both sexes and all ages and with a worldwide distribution 
(Murray et al., 2012). At least 50 million individuals have epilepsy worldwide (Ngugi et al., 
2010). Epilepsy has been ranked by the 2010 Global Burden of Disease study as the second 
most burdensome neurological disorder regarding disability-adjusted life years (DALYs) 
(Murray et al., 2012). This is partly due to a reduced life expectancy (Thurman et al., 2014, 
Thurman et al., 2017). The increased mortality among people with epilepsy relates to the 
underlying causes of epilepsy but can also be a consequence of the epilepsy and the seizures 
(Tomson et al., 2008; Thurman et al., 2014; Thurman et al., 2017). Death is well recognized 
in the context of a long-standing seizure, status epilepticus, but uncommon in conjunction 
with a seizure of normal duration. With this said, individuals with epilepsy are sometimes 
found dead, often in bed, despite having been under good health during the preceding days. 
When documented status epilepticus, trauma, and drowning have been excluded, and a post-
mortem examination does not reveal a structural or toxicologic cause for death, this is called 
Sudden Unexpected Death in Epilepsy (SUDEP) (Nashef, 1997). When SUDEP is witnessed, 
a preceding major convulsive seizure is observed in around 90% of cases and the patient dies 
in the aftermath of the seizure (Tomson et al., 2008). Despite increased attention over the last 
three decades and being the major epilepsy related cause of death (Thurman et al., 2014; 
Devinsky et al., 2016a), there is still uncertainty regarding the mechanisms, incidence and 
risk factors of SUDEP.  
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2 BACKGROUND 
 
2.1 DEFINITIONS AND CLASSIFICATION OF SEIZURES AND EPILEPSY 
2.1.1 Definition of seizures 
Epileptic seizures are the cardinal manifestations of epilepsy and are recurrent paroxysmal 
events characterized by stereotyped behavioral alterations reflecting the neural mechanisms 
involved in the epileptic process (Fisher et al., 2005). An epileptic seizure is a transient 
occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal 
activity in the brain (Fisher et al., 2005; Fisher et al., 2017a). 
 
2.1.2 Classification of seizures 
Based on the initial manifestations, seizures are classified into focal, generalized or unknown 
onset (Fisher et al., 2017a). Seizures are labelled focal when the epileptic activity is 
originated within networks limited to one hemisphere, and seizures are considered 
generalized when the epileptic activity has arisen in or rapidly engaged bilaterally distributed 
networks (Fisher et al., 2017a). Based on impact on awareness focal seizures are subdivided 
into focal aware and focal unaware, respectively. A focal seizure may evolve to a bilateral 
tonic-clonic seizure and is then named focal to bilateral tonic-clonic seizure (FBTCS) in the 
new classification system (Fisher et al., 2017b). Generalized seizures are subdivided further 
into: tonic-clonic, clonic-tonic, absences, myoclonic and atonic seizures. If there is 
insufficient evidence to characterize the seizure as focal or generalized it is labelled unknown 
(Fisher et al., 2017a). A schematic view of this new classification of seizures can be seen in 
figure 1. 
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Figure 1. ILAE 2017 Classification of Seizure Types Basic Version 
 
2.1.3 Definitions of Epilepsy 
Since 2005, the International League against Epilepsy (ILAE) has defined epilepsy 
conceptually as: “a disorder of the brain characterized by an enduring predisposition to 
generate epileptic seizures, and by the neurobiological, cognitive, psychological, and social 
consequences of this condition”. The definition of epilepsy requires the occurrence of at least 
one epileptic seizure (Fisher et al., 2005). Traditionally epilepsy has been defined clinically as 
the occurrence of two unprovoked seizures (Hauser et al., 1996) but since 2014 the ILAE has 
defined epilepsy in practical clinical terms as a “disease of the brain followed by any of the 
following conditions: (1) At least two unprovoked (or reflex) seizures occurring >24 h apart; 
(2) one unprovoked (or reflex) seizure and a probability of further seizures similar to the 
general recurrence risk (at least 60%) after two unprovoked seizures, occurring over the next 
10 years; (3) diagnosis of an epilepsy syndrome” (Fisher et al., 2014).  
 
Not all individuals who experience seizures have epilepsy. Seizures occurring in close 
proximity of an acute CNS injury or a metabolic, toxic or pharmacological disturbance, are 
termed provoked or acute symptomatic seizures. The distinction between unprovoked and 
  5 
acute symptomatic seizures is important, since the risk of recurrence of the latter is low once 
the acute phase of the CNS insult is over or the metabolic/toxic derangement is resolved 
(Hesdorffer et al., 2009; Beghi et al., 2010). Hence, this situation does not represent an 
“enduring predisposition” to generate seizures which is the hallmark of epilepsy. 
 
2.1.4 Classification of epilepsy 
The ILAE classification of the epileptic seizures and the epilepsies has been updated 
following scientific advances on the underlying mechanisms that have taken place in the last 
decades (Fisher et al., 2017a; Scheffer et al., 2017). Epilepsy types, previously called 
localization-related, generalized, or undetermined, are now divided into focal, generalized, 
combined generalized and focal or unknown (figure 2) primarily based on the types of 
seizures in the individual patient (Scheffer et al., 2017). Regarding classification of causes of 
epilepsy, the previous terms symptomatic, idiopathic and cryptogenic have been replaced by 
six etiological categories which are not mutually exclusive: genetic, structural, immune, 
infectious, metabolic, and unknown (Scheffer et al., 2017) (figure 2). 
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Figure 2. ILAE 2017 Classification of the epilepsies  
 
2.2 INCIDENCE AND PREVALENCE OF EPILEPSY  
The incidence of epilepsy varies from 24 to 71 per 100,000-person years in high income 
countries up to 190 per 100,000 in low/middle income countries (Forsgren et al., 2005; Ngugi 
et al., 2011; Singh and Trevick, 2016; Fiest et al., 2017). In a meta-analysis the incidence was 
61.4 per 100,000 person-years (48.9 per 100,000 person-years in high income countries and 
139.0 in low/middle income countries, respectively) (Fiest et al., 2017). In Sweden, the 
incidence of an unprovoked seizure was measured to be 56 per 100,000 person-years among 
adults and 89 among children in the county of Västerbotten (Sidenvall et al.,1993; Forsgren et 
al., 1996). In northern Stockholm the incidence of a first unprovoked seizure and epilepsy 
was 33.9/100,000 person-years, where the moderately lower incidence can be explained by 
under-ascertainment, particularly among the elderly (Adelöw et al., 2009). The higher 
  7 
incidence in low/middle-income countries may be explained by a greater exposure to 
perinatal risk factors, infections and traumatic brain injury and the different age structure of 
the populations at risk. The incidence of epilepsy is marginally higher in men, both in high 
income and in low/middle-income countries (Fiest et al., 2017). Around 4000-5000 
individuals are diagnosed with epilepsy in Sweden every year, which corresponds to a new 
patient every second hour (Forsgren et al.,2018). The incidence of epilepsy is highest at the 
extremes of the age. Over the last decades, age-specific incidence of epilepsy has decreased 
in the youngest age groups and increased in the older age groups (Forsgren et al., 2005; Singh 
et al., 2016). This could partly be explained by the improvement of perinatal care and the 
control of infectious diseases while the increased incidence during older age could be caused 
by increased life expectancy with an associated increase in epilepsy related diseases such as 
degenerative CNS disorders and stroke.  
 
The prevalence of active epilepsy varies from 4 to 8 per 1,000 inhabitants in high income 
countries. A population-based study in a Norwegian county showed that 0.65% of the 
population had active epilepsy (Syvertsen et al., 2015). In a meta-analysis of international 
studies, the point prevalence was 6.4 per 1,000 inhabitants (5.5 in high income countries) and 
lifetime prevalence 7.6 per 1,000 (Fiest et al., 2017). Active epilepsy is often defined as 
epilepsy with unprovoked epileptic seizures over the past five years or ongoing antiepileptic 
medication regardless of the time since last seizure (Forsgren et al., 2018). In 1985 the 
prevalence of active epilepsy in northern Sweden was 0.58% (Forsgren, 1992). Today, 
60,000 to 70,000 people are thought to have active epilepsy in Sweden. Of these, just over 
10,000 are children and over 50,000 are adults (Forsgren et al., 2018).  
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2.3 SEIZURE CONTROL    
The prognosis regarding seizure control has been suggested to fall into four different 
categories (Sander, 1993) and is relatively favorable in the majority of patients. One group 
(20-30%) has an excellent prognosis with high probability of spontaneous remission. In the 
second group, 30-40% will achieve remission with relatively simple pharmacological 
treatments and some will go in to spontaneous remission. In the third group (10-20%), the 
prognosis is uncertain. Here, the patient often responds to antiepileptic drugs (AEDs) but 
tends to relapse after treatment withdrawal. In the fourth group (20%) the prognosis is poor, 
and seizures persist despite extensive treatment efforts.  
 
The strongest prognostic predictor for seizure control under AED treatment is the etiology 
behind the epilepsy. Seizure remission is less common among patients with known or 
presumed etiology (Beghi et al., 2015). Individuals with neurological injury from birth have 
the lowest chance of achieving remission (Beghi et al., 2015. Those without epileptiform 
abnormalities on EEG and/or absence of GTCS have a higher likelihood of remission at 5 
years (Beghi et al., 2015). In a long term follow up study of children who were diagnosed 
with epilepsy in Turku, Finland between 1961-1964, 64% had been seizure free for the last 
five years in 1992. Predictive factors for seizure freedom were early response to AEDs and 
having idiopathic epilepsy (presumed genetic epilepsy) (Sillanpää et al., 1998). 
Recognizing that a significant proportion of people with epilepsy will eventually become 
seizure free and able to withdraw their medication without relapses, the ILAE has 
introduced the term epilepsy resolved for those who have been seizure-free for 10 years and 
without any AEDs during the last five years (Fisher et al., 2014). 
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2.4 MORTALITY IN EPILEPSY   
According to WHO, epilepsy is estimated to contribute 0.5% of world total "burden of 
disease" in terms of disability-adjusted life years (DALYs), which is comparable with 
psychotic disorders, Alzheimer's and other dementias (WHO 2000). This is partly attributed 
to the serious consequences of epilepsy. Of particular importance is the high mortality rate, 2 
- 3 times higher than expected (Nilsson et al., 1997; Mohanraj et al., 2006) and hence the 
significantly shortened lifespan. In a recent systematic review in high income countries 
(Thurman et al.,2017), the weighted standardized mortality ratio (SMR) in six population-
based studies was 2.3. The elevated mortality can be explained in part by the underlying 
causes of epilepsy such as brain tumors and cerebrovascular disease but may also be a 
consequence of epilepsy related deaths including seizure related accidental deaths, 
drownings, but also suicide in people with epilepsy (Fazel et al., 2013). Sudden Unexplained 
Death in Epilepsy (SUDEP) is the leading epilepsy-related cause of death (Tomson et al., 
2008; Thurman et al., 2014; Thurman et al., 2017). Among neurological diseases, SUDEP 
ranks only second to stroke in terms of potential years of life lost (Thurman et al., 2014). The 
risk of sudden unexpected death has been estimated to be 24-28-fold higher among young 
people with epilepsy than in the general population (Ficker et al., 1998; Holst et al., 2013). 
The cumulative lifetime risk of SUDEP differs according to age of epilepsy onset. In a model 
based on data from population-based studies, the lifetime risk for SUDEP (up to 70 years of 
age) has been estimated to 8.0% if epilepsy has its onset at 1 year of age, 7.2% with onset at 
15 years and 4.6% with onset of epilepsy at 30 years of age (Thurman et al., 2014). In the 
cohort from Turku in Finland cited above, 60 individuals, 24% of the study population had 
died 40 years after diagnosis, which was three times more than expected. Of the 60 deaths, 18 
individuals had died due to SUDEP where the risk was higher in those still having seizures 
(Sillanpää and Shinnar 2010). 
 10 
2.5 SUDDEN UNEXPECTED DEATH IN EPILEPSY 
2.5.1 Background, definitions, and classification 
Already in 1904, Spratling described epilepsy as a disease that: “destroys life suddenly and 
without warning through a single, brief attack...and does so in from 3 to 4% of all who suffer 
from it” (Spratling 1904). When Spratling describes it as a brief attack, SUDEP comes to 
mind. Despite awareness of the condition, it was not until some 20 years ago that more 
generally accepted definitions and classifications of SUDEP were introduced (Nashef, 1997; 
Annegers, 1997). Accordingly, SUDEP is generally defined as “the sudden, unexpected, 
witnessed or unwitnessed, non-traumatic, and non-drowning death in patients with epilepsy 
with or without evidence for a seizure, and excluding documented status epilepticus, in which 
postmortem examination does not reveal a structural or toxicologic cause for death’’(Nashef, 
1997). Annegers suggested that cases fulfilling the above definition fall into the “definite 
SUDEP” category; sudden deaths occurring in benign circumstances with no known 
competing cause for death but without autopsy are classified as “probable SUDEP” 
(Annegers, 1997).  Cases where SUDEP cannot be excluded, either because of limited 
information regarding death circumstances or there is a plausible competing explanation for 
death are classified as “possible SUDEP” (Annegers, 1997). Since then, modifications have 
been suggested to allow for more refined classification of cases (Nashef et al., 2012). The 
previously definite, probable and possible were unchanged but the category “definite SUDEP 
plus” was introduced for cases that fulfill the definition of definite SUDEP but where there is 
a concomitant condition (identified before or after death) that could contribute to the sudden 
death. The death may have been due to a combined effect of both conditions, and 
investigations do not confirm the concomitant condition to be the cause of death. The same 
applies to “Probable SUDEP plus” where a postmortem is missing. If an individual with 
epilepsy survives resuscitation for more than one hour after a cardiorespiratory arrest that has 
no structural cause identified after investigation, the term near-SUDEP was suggested 
(Nashef et al., 2012). 
  11 
 
2.5.2 Proposed mechanisms 
The pathophysiology of SUDEP is unknown, however, it is thought to be a combination of a 
seizure induced ictal and post-ictal brainstem, respiratory, and cardiac dysfunction where the 
seizure in most cases seems to be a focal to bilateral tonic-clonic seizure (FBTCS) (Ryvlin et 
al., 2019). Despite being separate seizure types, no distinction has been made in the SUDEP 
literature between a tonic-clonic seizure evolving from a focal or with a generalized onset. 
Henceforth in this work both types will be referred to as GTCS. Clinical observations 
demonstrate that SUDEP is preceded by a GTCS in the vast majority of cases, but it is 
unclear by which mechanisms seizures may cause SUDEP and the mechanisms can be 
heterogenous (Tomson et al., 2008; Ryvlin et al., 2019). Three main hypotheses have been 
put forward but the cause is likely most often a combination: a) cardiac arrhythmia or other 
cardiac dysfunction triggered by a seizure or b) respiratory failure triggered by a seizure, or c) 
a seizure triggered cancellation of cerebral activity (electro-cerebral shut-down) and 
subsequent failure of arousal (Tomson et al., 2008; Richerson et al., 2016; Ryvlin et al., 2019) 
(figure 3).  
 
Figure 3. Showing the hypothetical predisposing and precipitating factors leading to SUDEP  
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The MORTEMUS study (Ryvlin et al., 2013) analyzed 11 SUDEPs that had occurred during 
video-EEG monitoring. All 11 had terminal GTCS. Commonly the victims had had several 
GTCS in the days leading up to the death. A consistent pattern was present in all patients 
where cardiorespiratory data were available for analysis. There was an initial postictal 
tachypnoea, often with sinus tachycardia, followed by bradycardia or bigeminy, or irregular 
heart rhythm in all cases. Within three minutes after this, all patients suffered from transient 
or terminal cardiorespiratory dysfunction (i.e., apnoea and bradycardia), and then followed 
shortly afterwards by asystole. In summary, all died from a combination of apnea, 
bradycardia (not tachyarrhythmias) and an arousal failure. Furthermore, all SUDEP cases in 
the MORTEMUS study occurred at night. A postictal generalized EEG suppression (PGES) 
was observed in all SUDEP victims in the MORTEMUS study (Ryvlin et al., 2013). Arousal 
impairment, autonomic dysregulation and greater respiratory dysfunction are seen more 
frequently in patients with PGES (Devinsky et al., 2016a) but it is not observed after all 
GTCS, even in the same patient and the association between PGES and SUDEP is debated 
(Surges et al., 2011). 
 
One hypothetical model proposed for the mechanism of SUDEP (Massey et al., 2014) is 
based on the assumption that seizures activate neurons that project to the midbrain and 
medulla which in turn causes dysfunction of both the ascending arousal system and 
descending arousal system. With the seizure spreading to the midbrain it causes dysfunction 
of the ascending arousal system, including serotonergic neurons and this inhibition can then 
cause unresponsiveness and PGES postictally. Seizure spreading to the medulla may cause 
dysfunction of the descending arousal system, including the component that descends to the 
respiratory network in the medulla (Ryvlin et al., 2019). This, along with increased 
extracellular adenosine, may impair respiratory, cardiovascular and other autonomic control 
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neurons, while cortical activity is suppressed with PGES. Hypoventilation is then followed by 
post-ictal hypercapnia and hypoxia which can lead to bradycardia, asystole and death. 
 
The hypotheses discussed above assume a key role of the brain stem in SUDEP and recent 
studies have found brain stem abnormalities in SUDEP victims. In one study where MRIs 
were reviewed retrospectively, SUDEP victims had widespread brainstem volume loss 
evident before death (Mueller et al., 2018) and that volume loss in brainstem regions 
(periaqueductal grey/medulla oblongata) correlated with reduced heart rate variability. In a 
neuropathological postmortem analysis of 40 cases (14 SUDEP, 6 epilepsy controls, 13 non-
epilepsy controls) there were significant alterations in ventrolateral medulla in SUDEP cases 
with greater reduction in serotoninergic and galaninergic systems i.e. medullary respiratory 
neuronal groups (Patodia et al., 2018).  
 
In animal models of epilepsy, respiratory depression has been demonstrated as an early 
postictal event leading to SUDEP (Li and Buchanan, 2019). In one animal model, pre-
treatment with the selective serotonin reuptake inhibitor (SSRI) antidepressant fluoxetine, 
could prevent postictal respiratory arrest (Tupal and Faingold, 2006). In human subjects with 
epilepsy, preliminary data indicates that selective serotonin reuptake inhibitors can reduce 
post ictal desaturation, interestingly in focal seizures but not focal to bilateral tonic-clonic 
seizures (Bateman et al., 2010).  
 
2.5.3 Genetic factors and SUDEP 
Genetic factors can also play a certain role and may potentially help identify patients at risk 
of SUDEP. In one study of 61 SUDEP patients, clinically relevant mutations were found in a 
substantial amount of cases; In 22% there were cardiac arrhythmia genes and in one fourth of 
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the cases there were epilepsy genes (Bagnall et al., 2016). The genes involved are often so-
called brain-heart genes which can both contribute to the cause of the epilepsy and make the 
individual more vulnerable to arrythmias and sudden death. Animal models have found at 
least nine different brain-heart genes that may contribute to a genetic susceptibility for 
SUDEP (Glasscock, 2014). Many of these gene defects are located in ion channel genes or 
genes modulating ion channel function that predispose humans and/or animal models to both 
seizures and fatal cardiac arrhythmias or in genetic defects in the serotonergic or autonomic 
systems (Dlouhy et al., 2016). 
 
2.5.4 Incidence of SUDEP 
Due to methodological limitations in previous studies, estimates of the incidence of SUDEP 
are somewhat uncertain (Devinsky et al., 2016a). In a recently published Practice guideline 
summary based on a systematic review and meta-analysis carried out by the American 
Academy of Neurology (AAN) and the American Epilepsy Society (AES) (Harden et al., 
2017) the authors found the current evidence level with respect to the incidence of SUDEP to 
be low to moderate. Unfortunately, SUDEP does not yet have an International Classification 
of Disease code which hampers registration and research on SUDEP. Furthermore, SUDEP is 
both underreported and under recognized by clinicians who complete death certificates and 
also by medical examiners (Schraeder et al., 2009).  
 
A systematic review and pooled analysis of high-quality population studies estimated the 
crude annual incidence of SUDEP to be 1.16 (0.95-1.36) per 1,000 persons with epilepsy 
(Thurman et al., 2014). Estimates were based on three population-based studies where 
SUDEP cases were ascertained through the Medical Examiner, Coroner, or hospital post-
mortem registers in the US or UK, and the SUDEP incidence was calculated based on a 
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presumed prevalence of epilepsy in the catchment area (Leestma et al., 1989; Langan et al., 
1998; Opeskin and Berkovic, 2003).  However, the risk of SUDEP varies greately within the 
epilepsy population (Tomson et al., 2008). In fact, reported SUDEP incidence ranges from to 
0.09 per 1000 person-years in newly diagnosed patients in population-based studies up to 9 
per 1000 person-years in treatment resistant patients (Tomson et al., 2008; Devinsky et al., 
2016a). Hence, there is a 100-fold range in SUDEP incidence within the epilepsy population 
(Téllez-Zenteno et al., 2005; Tomson et al., 2008). Previous studies have indicated greater 
risk among males (Hesdorffer et al., 2011) and at ages between 20-40 years (Holst et al., 
2013, Thurman et al., 2014), whereas SUDEP has been considered rarer in children (Donner 
et al., 2001; Weber et al., 2005; Berg et al., 2013; Harden et al., 2017) and older age groups 
(although rarely assessed).  
 
2.5.5 Circumstances surrounding death in SUDEP 
SUDEP is in most cases unwitnessed and occurs most often during sleeping hours (Lamberts 
et al 2012) where victims are often found dead in bed (Kloster and Engelskjon, 1999; 
Opeskin and Berkovic, 2003). When occurring during sleeping hours, SUDEP was four times 
more likely to be unwitnessed than during awake hours (Lamberts et al., 2012). It thus seems 
that SUDEP frequently occurs when patients are unattended or without supervision. Early 
support for this notion came from a study of children with epilepsy in residential care (Nashef 
et al., 1995). In this group, all SUDEPs occurred while the children were on leave from the 
institution and did not have their regular supervision (Nashef et al., 1995). This is also in line 
with a case-control study (Langan et al., 2005) which indicated a protective role for a 
listening devise or regular checks during the night or sharing a bedroom with someone 
capable of giving assistance. Likewise, another study reported SUDEP to be more common in 
an epilepsy center with less supervision at night compared to another comparable epilepsy 
center with more supervision at night (van der Lende et al., 2018). In the previously cited 
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review from the AAN/AES (Harden et al., 2017) the authors considered lack of nocturnal 
supervision, and absence of nocturnal listening device to be risk factors with moderate 
confidence. SUDEP victims are often found in the prone position. In one study, which 
combined information from several studies, where body position was documented, 73% of 
253 SUDEP victims were found in a prone position (Liebenthal et al., 2015). In the 
MORTEMUS study, the victim usually turned to a prone position during the seizure (Ryvlin 
et al., 2013).  
 
2.5.6 Risk factors in SUDEP 
With SUDEP being the major epilepsy related cause of death in people with epilepsy 
(Thurman et al., 2014; Thurman et al., 2017), the search for SUDEP risk factors has been 
intense over the past three decades. This has been done mainly in retrospective case-control 
studies where clinical characteristics have been compared between SUDEP victims and living 
people with epilepsy or non-SUDEP deaths. These studies vary considerably in risk factors 
analyzed, study population size, selection of controls and in generalizability. The most 
common approach has been to use living epilepsy controls to identify epilepsy patients at 
risk, i.e. what separates living epilepsy patients from those who have died from SUDEP. An 
overview of such studies is presented in Table 1.  
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Table 1. Case-control studies evaluating risk factors associated with SUDEP 
Studies (year, 
country) 
Study population Cases/controls; N Increased risks 
Nilsson (1999, 
2001) Sweden 
Hospital discharge 
register 
57/171 More than 2 seizures/year  
Polytherapy with AEDs 
Onset of epilepsy under 15 years  
Changes of AED dose  
Use of antipsychotic drugs 
 
Langan (2005) 
UK 
Multiple sources 154/616 Frequent GTCS  
History of GTCS  
Many AEDs ever used 
Current use of carbamazepine 
Supervision or special precautions at 
night protective 
Hitiris (2007) 
Scotland 
Epilepsy center 62/124  Seizure during last year.  
Onset of epilepsy before 15 years 
Surges (2010)  
UK 
Epilepsy center 
adults with 
pharmacoresistant 
focal epilepsies 
19/19  Frequent GTCS 
Aurlien (2007) 
Norway 
Multiple sources 19/63  Females on lamotrigine  
Walczak (2001)  
USA 
Epilepsy centers 20/80 GTCS 
Polytherapy 
Onset of epilepsy <15 years  
Epilepsy duration >30 years  
Mental retardation 
 
Most studies have been relatively small with well below 100 cases in each, except one study 
from the UK (table 1.) (Langan et al., 2005). There have also been studies using controls with 
epilepsy that have died from non-SUDEP causes, which can be used to shed light on the 
circumstances surrounding the death more than to identify risk factors (Kloster and 
Engelskjon, 1999; Opeskin and Berkovic, 2003; Tomson et al., 2008).  
 
The majority of case-control studies have shown frequent GTCS (focal to bilateral or 
generalized tonic-clonic seizures) to be a significant risk factor (Nilsson et al., 1999; McKee 
and Bodfish, 2000; Walczak et al., 2001; Langan et al., 2005; Hitiris et al., 2007). In one 
study, the risk of SUDEP was 23 times higher in those who had experienced any seizure 
during the year of observation compared with seizure free patients (Nilsson et al., 1999) and 
all three case-control studies that allowed for quantifying the risk by different levels of 
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seizures found that the risk increased with the frequency of GTCS (Walczak et al., 2001, 
Langan et al., 2005). When data from four of the case-control studies, with living epilepsy 
controls, cited above (Nilsson et al., 1999; Walczak et al., 2001; Langan et al., 2005; Hitiris et 
al., 2007) were pooled  (Hesdorffer et al., 2011) the following were identified as  risk factors 
for SUDEP: male sex (OR 1.42), epilepsy onset before age 16 years (OR 1.72), disease 
duration of more than 15 years (OR 1.95), and number of GTCS per year (OR 5.07 for one to 
two GTCS per year and OR 15.46 for three or more of these seizures per year). In the more 
recent systematic review from the AAN/AES (Harden et al., 2017) GTCS was identified as 
the major risk factor (high confidence) and SUDEP risk increased with increasing frequency 
of GTCS (moderate confidence). Alcohol abuse has also been associated with SUDEP 
(Hesdorffer et al., 2011; Harden et al., 2017). The AAN/AES found low evidence that the 
following risk factors were associated with SUDEP risk: nocturnal seizures, lamotrigine use 
in women, never been treated with an AED, number of AEDs used overall, extratemporal 
epilepsy, intellectual disability, male sex, anxiolytic drug use, any specific AED, heart rate 
variability (Harden et al., 2017). Furthermore, the AAN/AES guidelines found other 17 
previously suggested risk factors to have very low or conflicting evidence regarding SUDEP 
risk.   
 
2.5.7 Antiepileptic drug treatment, adherence and SUDEP risk 
Risk factors related to drug treatment are among the most important since these are amenable 
to changes and thus represent opportunities for prevention of SUDEP. A key question is 
whether AED treatment also affects the risk of SUDEP. As SUDEP is related to seizure 
occurrence, it is reasonable to assume that an effective drug treatment would reduce the 
incidence of SUDEP. Excess risk of SUDEP has been observed in relation to polytherapy 
(Nilsson et al., 1999; McKee and Bodfish, 2000; Walczak et al., 2001), but in a pooled 
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analysis of data from four studies, AED polytherapy was not associated with increased risk of 
SUDEP after adjustment for GTCS frequency (Hesdorffer et al., 2012). These findings are 
supported by those of a meta-analysis of 112 randomized controlled trials of adjunctive AED 
treatment for refractory focal seizures, including 18 definite or probable SUDEPs; The risk of 
SUDEP was much lower, OR 0.17 (95 % CI, 0.05–0.57), among those randomized to 
effective add-on AED treatment compared to add-on placebo (Ryvlin et al., 2011). 
Additionally, in the video-EEG monitoring study (MORTEMUS), SUDEP occurred after 
tapering AED treatment by at least 50% in all 10 cases where such information was available 
(Ryvlin et al., 2013). Taken together these data suggest that no treatment and/or tapering 
treatment is a risk factor. The systematic review stated that not adding an AED when patients 
are medically refractory was a risk factor with moderate confidence level (Harden et al., 
2017).   
 
Carbamazepine treatment (Timmings, 1993, Langan et al., 2005) and high plasma 
concentrations of carbamazepine (Nilsson et al., 2001) were associated with a slight increase 
in risk for SUDEP. This is not implausible since carbamazepine can reduce heart-rate 
variability (Persson et al., 2003), which has been a predictor of increased sudden death in 
other conditions. A small case-series suggested an association between use of lamotrigine in 
women with idiopathic epilepsy and SUDEP (Aurlien et al., 2007). It should be emphasised, 
however, that observations on SUDEP risk with these two AEDs have not been confirmed in 
other studies such as the pooled analysis of four case-control studies, when adjustment was 
made for seizure frequency (Hesdorffer et al., 2012) and a meta-analysis of 42 randomised 
controlled studies of lamotrigine found no increase (Tomson et al., 2013). 
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Poor adherence to AEDs has been suggested as a risk factor for SUDEP (Téllez-Zenteno et 
al., 2005; Tomson et al., 2005; Monté et al., 2007). Data are, however, so far non-conclusive 
due to methodological limitations of previous studies. In a retrospective cohort study, Faught 
and colleagues (Faught et al., 2008) used Medicaid claims data to evaluate adherence to 
treatment in more than 33,000 patients with AED prescriptions. Non-adherence was 
associated with a more than threefold increase in mortality compared to adherence. A similar 
result was observed in a large study from the UK (Risdale et al., 2011). Unfortunately, both 
these investigators analysed all causes of mortality and not SUDEP specifically. In summary, 
SUDEP in relation to adherence has not been specifically studied. 
 
The systematic review (Harden et al., 2017) concluded that the evidence is low for any 
specific AED, or for lamotrigine use in women to be associated with increased SUDEP risk, 
and very low or conflicting for a difference between monotherapy vs. polytherapy or for 
psychotropic drug use. The practice guideline summary stressed the importance of therapy 
adherence to maintain freedom from GTCS, although non-adherence as a SUDEP risk factor 
has not been assessed appropriately.  
 
2.5.8 Other drug treatment and SUDEP risk 
It is conceivable that drugs other than AEDs could affect SUDEP risk. Based on data from an 
epilepsy mouse model, it has been suggested that treatment with antidepressants of the SSRI 
type, could reduce the SUDEP risk (Tupal and Faingold 2006). The proposed mechanism is 
by prevention of postictal respiratory arrest. Pharmacological treatment, with drugs such as 
beta blockers has been used successfully in prevention of sudden cardiac death in patients at 
high risk for reasons such as ischemic heart disease, congestive heart failure and post 
myocardial infarction (Arshad et al., 2008). Although a different population, it is reasonable 
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to consider the possibility of a preventive effect of drugs such as beta blockers and statins on 
SUDEP in epilepsy patients, given the similarities of the final event. However, the effects in 
prevention of SUDEP with SSRIs, beta blockers or statins have never been assessed. It is 
very unlikely that these drugs will be analysed in randomized controlled trials unless 
epidemiological data supports their effectiveness. 
  
2.5.9 Vagus nerve stimulation, epilepsy surgery and SUDEP 
It is unclear if vagus nerve stimulation reduces the risk for SUDEP. One study (Annegers et 
al., 2000) showed a lower than expected rate of SUDEP in a cohort of treatment resistant 
epilepsy patients treated with vagus nerve stimulation while another study did not 
(Granbichler et al., 2015). Since seizure control is the most likely approach to reduce the 
risk of SUDEP, successful epilepsy surgery may also reduce the risk of SUDEP. In a large 
follow up study of 583 surgical patients, SUDEP was significantly associated with seizure 
control (p=0.001) (Sperling et al., 2005). In 18 of 19 SUDEP deaths, patients were not 
seizure free. In another study that included 305 patients who underwent temporal lobe 
epilepsy surgery over a 20-year period, SUDEP rates were lower than those reported for 
similar patient populations with chronic epilepsy (Hennessy et al., 1999).  
 
2.6 SUMMARY AND CONCLUDING REMARKS ON THE CURRENT STATE OF 
KNOWLEDGE  
Although SUDEP has attracted increasing attention from the scientific community during the 
last 20 years, important gaps in knowledge still exist that hamper the development of 
methods aiming at prevention of this, the most devastating consequence of epilepsy. We are 
still missing large population-based studies on the incidence of SUDEP, which is important 
both in order to understand whom to target with preventive measures and how to assess 
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effectiveness of interventions. Our understanding of the circumstances surrounding SUDEP 
is incomplete which is a major limitation when it comes to development of seizure 
monitoring and potential SUDEP-preventing devices. Finally, our understanding of risk 
factors for SUDEP is limited to a few established risk factors. There is only one risk factor 
with high confidence level, five with moderate and 17 with low or very low as assessed in the 
recent systematic review (Harden et al., 2017). The low confidence level is often due to 
methodological issues. In particular, more data are needed to understand the potential role of 
pharmacological treatment for SUDEP prevention.  
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3 AIMS 
3.1 General aims  
The objective of the thesis was to provide new information on the incidence, circumstances, 
and risk factors of SUDEP, with the overall aim of providing a basis for the development of 
future actions to prevent this devastating consequence of epilepsy. 
3.1.1 Specific aims 
The specific aims were to study: 
1. The age and sex specific incidence of SUDEP in the Swedish population (paper I). 
2. The circumstances surrounding SUDEP such as living conditions, if death was 
witnessed, place, time and body position at death (paper II).  
3. The influence of clinical factors including GTCS, nocturnal seizures and comorbid 
diseases on the risk of SUDEP (paper III). 
4. The risk of SUDEP in relation to AED treatment, including mono vs. polytherapy, 
adherence and treatment with SSRIs, statins, beta-blockers and antipsychotic drugs 
(paper IV). 
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4 SUBJECTS AND METHODS 
 
4.1 Subjects 
4.1.1 Overview of study population  
The project is based on a study population (n=78 524) which comprises all persons living in 
Sweden at 1. July 2006, who at some point during 1998-2005 where registered with the 
diagnosis code for epilepsy (ICD G 40) in the Swedish National Patient Register (SNPR). 
The SNPR contains all patients hospitalized (with total national coverage from 1987) or 
managed in hospital-based ambulatory care (since 2001) in Sweden. Although not yet 
formally validated for epilepsy, the register has been validated for several diagnoses, and 
shown a high accuracy (Ludvigsson et al., 2011). Each individual’s outpatient visit or 
hospital discharge diagnosis (ICD code) is linked with their unique personal identification 
number. 
 
4.1.2 SUDEP case ascertainment  
To identify cases of SUDEP, the study population was linked to the National Cause-of-Death 
Register. During the follow-up time from July 1, 2006 to December 31, 2011, we identified 
9605 deaths. All death certificates in the study population between 1 July 2006 and 31 
December 2011 with epilepsy mentioned on death certificate and all deaths during 2008 
(n=3166) were reviewed by Olafur Sveinsson (figure 4). Based on the information in the 
death certificates, obvious non-SUDEP deaths were excluded from further analysis. For all 
others we analyzed patient medical records, autopsy and police reports (Olafur Sveinsson) 
and information was extracted using a standardized protocol. Those who did not have 
epilepsy and obvious non-SUDEP cases were excluded. Two neurologists (Olafur Sveinsson 
and Torbjörn Tomson) reviewed the remaining potential SUDEP cases and classification was 
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made through consensus. When needed, a forensic pathologist was consulted. By using this 
methodology, 329 SUDEP cases were collected.   
 
Figure 4. Flow chart over case and control selection in papers II-IV  
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4.1.3 Selection of controls 
From the study population, five epilepsy controls (n=1275) per SUDEP case, of the same sex, 
who were alive at the case´s time of death, were randomly selected by the National Board of 
Health and Welfare. The index date for the controls was time of death for the matched case. 
Medical records were attained for 97% (n=1232) of the controls. After case review, 6.8% 
(n=84) of them were judged not to have epilepsy. This left 1148 individuals who served as 
controls (figure 4).  
 
4.2 METHODS 
4.2.1 The incidence of SUDEP (paper I) 
The SUDEP incidence study was based on an in-depth assessment of all deaths for one year, 
2008. All individuals with a hospital-based ambulatory care or hospital discharge diagnosis of 
epilepsy in the Swedish National Patient Registry during 1998-2005 who were alive on 
January 1st, 2008 (n=57 775) were included. We identified deaths during 2008 by linkage to 
the National Cause-of-Death Registry. Death certificates for all who died during 2008 (n= 
1891) were retrieved. Obvious non-SUDEP were excluded and information collected on 
potential cases as described above. Two neurologists (Olafur Sveinsson and Torbjörn 
Tomson) classified the SUDEP cases (n=99) according to two different proposals, the 
Annegers’ criteria (Annegers, 1997) and the unified definition of SUDEP proposed by 
Nashef et al (Nashef et al., 2012), respectively. The SNPR was used to identify those in the 
epilepsy study population that had psychiatric comorbidity registered during 1998-2005 (ICD 
10 code F 00-99).   
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4.2.2 Circumstances of SUDEP (paper II) 
Information from all 329 SUDEP (definite, probable, and possible according to Annegers’ 
criteria) cases identified 2006 to 2011, regarding circumstances was extracted from patient, 
autopsy and police records. The following information was extracted: living conditions 
(living alone, with others, sharing a bedroom), body position (prone, supine, sitting, lateral, 
on the side or unknown) when found dead, witnessed or not (individuals observed from a 
healthy state until dead were considered witnessed), seizure in conjunction with death, or 
indirect signs indicating seizure, time of day, time of week, time of year, location (at home 
and where, outside of home or in hospital). Time of death was classified as: Daytime (08.00-
16.00), Evening (16.00-00.00) or Nighttime (00.00-08.00). In seventeen cases, the day but 
not time of death could be determined. Death during June, July and August was categorized 
as occurring during summertime. Death during all other months was classified as other. 
Weekends and public holidays were considered as non-working days while all other were 
working days.   
 
Autopsied non-SUDEP group  
Since living epilepsy controls cannot be used as controls when it comes to the circumstance 
of death we used  60 cases with an initial suspicion of SUDEP, but for which autopsy records 
revealed another definite cause of death with the following being the most common causes; 
mycocardial infarction (21), heart failure (8), traumatic brain injury (7), pneumonia (6), status 
epilepticus (5). These autopsied non-SUDEP cases provided a reference group for our 167 
definite SUDEP cases, who also had undergone an autopsy.  
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4.2.3 Clinical risk factors in SUDEP (paper III) and pharmacological 
treatment and SUDEP risk (paper IV) 
Of the 329 SUDEP cases described above, only definite (n=167) and probable (n=88) but not 
possible SUDEP cases (n=73) were used for case-control analyses. For all cases and controls, 
we used patient records to collect information as described in paper II above and additionally 
on type of epilepsy, etiology (Scheffer et al., 2017), epilepsy onset, duration of epilepsy, 
history of GTCS (including both generalized tonic-clonic seizures and focal to bilateral tonic-
clonic seizures) (Fisher et al., 2017), presence and frequency of nocturnal GTCS during last 
year of observation, presence of other seizures during the last year of observation, history of 
nocturnal seizures, history of nocturnal GTCS, presence of nocturnal GTCS during last year 
of observation, intellectual disability, AEDs and whether the patient had undergone epilepsy 
surgery or had ongoing treatment with vagus nerve stimulation (VNS).  
 
By means of ICD codes from the SNPR we obtained information on pulmonary, 
cardiovascular and psychiatric comorbidity (from 1997 to death or index date). Information 
on highest educational level was attained from the Longitudinal integration database for 
health insurance and labor market studies (LISA), which holds annual registers since 1990 
and includes all individuals 16-74 years of age. In the LISA register, this information is 
recorded as missing for individuals below 16 years and for those who did not attend regular 
school due to intellectual disability.  
 
Information from Swedish Prescribed Drug Register  
The National Prescribed Drug Register records information on all prescribed drugs dispensed 
at Swedish Pharmacies since July 2005. Medications are classified according to Anatomical 
Therapeutic Chemical (ATC) classification system and in the present study, ATC code N03A 
was used for AEDs. For the current analysis we focused on the seven most frequently used 
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AEDs among our cases and controls. Using data from this register we classified AED usage 
in the following way; Taking an AED: AED dispensed within 90 days of death or index date, 
since in Sweden, drug dispensing cannot be for longer than 90 days at a time; Not taking an 
AED: no AED dispensed within 360 days of death or index date; Undetermined group: AED 
dispensed between 90-360 days but not within 90 days from death or index date.  
 
Monotherapy: only one AED dispensed within 90 days of death or index date: Polytherapy: 
two or more AEDs dispensed within 90 days of death or index date; We also collected 
information on concomitant treatment with neuroleptics (ATC N05A), antidepressants (ATC 
N06A), beta blockers (ATC C07A) and statins (ATC C10A). Cases and controls were 
considered to use the above-mentioned medications if they had been dispensed within 90 
days of death or index date. 
 
4.3 Statistical analysis 
For all papers, the final statistical analysis was performed with SAS software (SAS software, 
Version [9.4] of the SAS System for [MS Windows], SAS Institute Inc.).  
 
Paper I 
Incidence rates of SUDEP were estimated together with exact 95 % confidence intervals 
(CIs) (Garwood, 1936). We also calculated incidence rate ratios in relation to sex and 
psychiatric comorbidities, together with 95% exact confidence intervals (Sahai 1996). 
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Paper II 
P-values for comparisons between SUDEP cases and non-autopsied controls were calculated 
from the two-sided t distribution for means and with the chi-squared distribution for 
proportions and incidences. Incidence was calculated as number of SUDEP cases per 
calendar month, weekday and working days and non-working days respectively, divided by 
the number of person years.  
 
Papers III-IV 
In papers III and IV the association between SUDEP and potential risk factors were estimated 
by ORs with 95% CIs calculated by conditional logistic regression to account for matching 
by sex and calendar time. As the control participants were sampled with an incidence density 
method, the ORs can be interpreted as incidence rate ratios (Vandenbroucke and Pearce, 
2012). In paper III, ORs were adjusted for age and sex (model 1), age, sex and GTCS 
frequency (model 2) and age, sex, GTCS frequency and nocturnal GTCS last year of 
observation (except in the analyses of seizures), living conditions and AEDs (model 3). In 
paper IV, ORs were adjusted for age and sex (model 1), age, sex, duration and type of 
epilepsy, living conditions (sharing bedroom), intellectual disability, substance abuse, alcohol 
dependence, education level (model 2). Model 3 is adjusted for the same variables as model 2 
together with history of GTCS, GTCS frequency last year of observation and nocturnal 
GTCS last year of observation.  In the thesis, results of model 3 are discussed unless 
otherwise stated. We used proportion attributable to interaction (AP) (Andersson et al., 2005) 
in paper III to assess interaction between GTCS during last year of observation (yes/no) and 
sharing a bedroom (yes/no), defined as departure from additivity of effects. The formula for 
AP is: (OR11 – OR10 – OR01 + 1) / OR11, where OR11 indicates doubly exposed (having 
GTCS and sleeping alone) and OR01 or OR10 indicate either one exposure (sleeping alone or 
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having GTCS). The reference group is those with neither exposure, and the ORs were 
adjusted for age and sex (matching variable).  
 
4.4 Ethical considerations 
Our study design relies on access to personal data from different registries, individual 
medical records and for potential cases also from autopsy and police reports, and without 
obtaining individual informed consent from relatives (for cases) or directly from patients (for 
controls). Apart from the methodological issues with in particular risk of substantial loss of 
cases and controls and thus representativeness, we considered that approaching relatives and 
in particular patients to obtain informed consent may cause harm. Surveys among 
neurologists have shown that most do not inform their epilepsy patients about SUDEP 
(Morton et al., 2006). An information letter on SUDEP from the research group to the 
patients, whether through their physician or not, could pose anxiety and unreasonable concern 
for future health risks. For these reasons we concluded that attempts to obtain informed 
consent would cause more harm than benefit for the patients involved. To avoid ordering 
patient records and information for more controls than necessary, we first identified the cases. 
After extracting information from medical records and registers for both cases and controls, 
all individuals were deidentified and data kept anonymized. The Ethics Committee of 
Karolinska Institutet approved the study and granted that individual informed consent was not 
required.  
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5 MAIN RESULTS 
 
5.1 The incidence of SUDEP (paper I) 
During 2008, 1890 individuals from the study population died. Of these, 99 met Annegers‘ 
SUDEP criteria (49 definite, 19 probable, and 31 possible). Definite and probable SUDEP 
accounted for 3.6% of all deaths in the study population during the year 2008, and 5.2% 
when possible was included. In the age group 0-15 years, the relative contribution of SUDEP 
(definite, probable and possible) to overall deaths was 36.0% (9/25), 21.3% (34/160) between 
16-50 years and 3.3% (56/1706) above 50 years. SUDEP incidence was 1.20/1000 person-
years (definite/ probable according to Annegers’ definition), 1.24/1000, 
(definite/probable/SUDEP-plus according to Nashef’s definition) and 1.74/1000 if possible 
SUDEP was included according to the former definition. Although with overlapping 
confidence intervals, the trend was for higher incidence of definite/probable SUDEP among 
those above 50 years (figure 5) and the proportion of possible cases increased with age 
(figure 6). Incidence was higher in males (1.41/1000), than in females (0.96/1000), but only 
when possible SUDEP was included. Notably, there was no SUDEP case among girls <16 
years but seven boys. The incidence was higher among those with psychiatric comorbidities 
compared to those without, particularly among females, rate ratio 5.15, 95% CI: 2.17-13.10. 
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Figure 5. Incidence of SUDEP over different ages both for definite and probable and 
definite, probable and possible 
 
Out of the 99 cases with definite, probable, or possible, SUDEP was listed as the immediate 
cause of death on the death certificate in one case only: In 27 out of 99 cases either SUDEP, 
seizures, or epilepsy was indicated as the immediate cause of death. Epilepsy was mentioned 
in any position of the death certificate in 63.6% of the 99 SUDEP cases and in 15.2% of the 
1890 individuals with an epilepsy diagnosis who died during 2008. 
 
5.2 Circumstances of SUDEP (paper II) 
Of the 329 SUDEP deaths (definite (n=167), probable (n=89) possible (n=73), more than half 
(58%) occurred at night and 91% died at home, whereof 65% were found deceased in bed 
(figure 6). Death was witnessed in 17% of all SUDEP cases. When a seizure was witnessed in 
conjunction with SUDEP (n=49) all were GTCS. In four witnessed cases no seizure was 
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observed and in three cases this was uncertain. In two thirds of cases (67%) there was either a 
witnessed seizure (15%) or indirect indications of a seizures (52%).  
 
If SUDEP occurred during the night (58%) compared to during the day or evening (37%), it 
was more likely not to be witnessed (p=0.013). In the SUDEP cases where body position was 
documented (43%), more than two thirds (70%) were found prone (figure 6). Dying at night 
made it more likely (80%) to be found prone than other times (55%) (p<0.001). Among adult 
SUDEP cases, 75% were living alone, and only 14% of all SUDEP cases shared a bedroom 
(figure 6). We found a non-significant indication for higher incidence during the summer 
months compared with the rest of the year; 0.96 vs. 0.79 per 1000-person years (p=0.86) and 
on non-working days, compared with working days, 0.94 vs. 0.79 per 1,000-person years 
(p=0.19).  
 
Figure 6. Circumstances at death in 329 SUDEP cases; proportion (%) of cases 
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In comparison to the the autopsied non-SUDEP group, the definite SUDEP patients died 
more often unwitnessed, with a preceding seizure, at home, in bed during the night, were 
more often found in the prone position and to live alone (table 2).  
Table 2. Differences between definite SUDEP cases (n=167) vs autopsied non SUDEP 
deaths (n=60) in relation to living conditions and circumstances surrounding death 
Table 2. Differences between definite SUDEP cases (n=167) vs autopsied non SUDEP deaths (n=60) in 
relation to living conditions and circumsta ces surrou ding death 
  Definite SUDEP 
(n=167) 
 
Autopsied 
non- SUDEP 
(n=60) 
p value 
    
  
Died during the 
night 
59% 22% p<0.001 
Died at home 89% 43% p<0.001 
Witnessed  13% 67% p<0.001 
Seizure when 
witnessed 
95% 21% p<0.001 
Prone position 82% 16% p<0.001 
Lived alone 65% 52% p=0.014 
Shared a bedroom 10% 45% p<0.001 
    
    
 
 
 
 
P value, comparison between definite SUDEP cases and non-SUDEP deaths with autopsy. 
5.3 Clinical risk factors in SUDEP (paper III) 
A clinical and demographic overview for the 255 SUDEP cases (167 definite, 88 probable) 
and 1148 controls included in analyses of paper III and IV can be seen in table 3. The cases 
had somewhat longer duration of epilepsy, more often focal epilepsy and of structural origin, 
and lived more often alone (68%) than controls (27%) (table 3).  
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Table 3. Demographic and clinical characteristics for cases and controls (papers III and IV) Table 3. Demographic and clinical characteristics for cases and controls (papers III and IV) 
    
 Cases  Controls  
   
N (%) 255  1148 
Mean age at death/index (range) 47 (4-92) 39 (3-94) 
Mean age at epilepsy diagnosis (range) 22.4 (0-86) 20.0 (0-86) 
Mean duration of epilepsy in years 
(range) 
24 (1-81) 20 (1-78) 
   
Type of epilepsy    
Generalized n (%) 37 (14.5) 267 (23.3) 
Focal n (%) 186 (73.0) 794 (69.3) 
Focal and generalized n (%) 10 (4.0) 31 (2.7) 
Unknown n (%) 22 (8.6) 56 (4.9) 
   
Causes of epilepsy   
Genetic n (%) 48 (18.8) 303 (26.4) 
Structural 129 (50.6) 444 (38.7) 
Infectious n (%) 12 (4.7) 42 (3.7) 
Metabolic n (%) 2 (0.8) 9 (0.8) 
Autoimmune n (%) 2 (0.8) 10 (0.9) 
Unknown n (%) 66 (25.9) 359 (31.3) 
   
Living conditions   
Sharing household and bedroom n (%) 32 (12.5) 391 (34.1) 
Sharing household but not bedroom n 
(%) 
49 (19.2) 398 (34.7) 
Not sharing household n (%) 174 (68.2) 304 (26.5) 
Unknown n (%) 0 55 (4.8) 
   
Highest education   
Post-secondary education n (%) 26 (10.2) 168 (14.6) 
High school/secondary education n (%) 86 (33.7) 359 (31.3) 
Primary education n (%) 86 (33.7) 297 (25.8) 
Missing education n (%)a 57 (22.4) 324 (28.2) 
   
a Below 16 and those who did not attend regular school. 
 
 
 
Those with a history of GTCS had a tenfold increased SUDEP risk and the risk was increased 
to 32-fold with 4-10 GTCS during the last year of observation (table 4). When a history of 
nocturnal GTCS was present, a nine-fold SUDEP risk was observed and a 15-fold risk was 
seen if nocturnal GTCS were present during the last year of observation (table 4). No 
increased risk of SUDEP was seen in those experiencing exclusively non-GTCS during the 
preceding year. There was a fivefold increased risk of SUDEP among those living alone, 
while the risk was reduced to twofold when sharing household but not bedroom. A 59% 
reduced SUDEP risk was associated with treatment with vagus nerve stimulation (table 4). 
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No association between level of education and SUDEP risk was observed.  Individuals with a 
previous diagnosis of substance abuse or alcohol dependence had a twofold increased risk of 
SUDEP. Mental health disorders and intellectual disability, structural etiology, focal or focal 
and generalized epilepsy, longer duration of epilepsy and young age at epilepsy onset, were 
not associated with SUDEP, once we adjusted for frequency of GTCS. Albeit, epilepsy of 
unknown type remained associated with SUDEP.  
 
Analyses of the combination of GTCS and living conditions indicated that compared to those 
without GTCS and who shared their bedroom with someone, individuals who experienced ≥4 
GTCS during the last year of observation had 20 times increased risk if they shared their 
bedroom with someone, 34 times increased risk if they shared household but not bedroom 
and 82 times increased SUDEP risk if they lived alone. Interaction analysis indicated that 
individuals experiencing ≥1 GTCS and not sharing a bedroom with someone had 67-fold 
increased risk of SUDEP compared to individuals not having GTCS, who shared their 
bedroom with someone, with AP estimated at 0.69 (95% CI 0.53-0.85).   
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Table 4. Odds ratio (OR) and 95% confidence interval (CI) of SUDEP in relation to type and 
frequency of seizures and treatment 
Table 4. Odds ratio (OR) and 95% confidence interval (CI) of SUDEP in relation to type and frequency of 
seizures and treatment 
    Model 1a 
 
Model 3b 
 No. 
Cases   
No.  
Controls  
OR (95% CI) OR (95% CI) 
History of GTCS  
No 4 174 1 1 
Yes 251 943 10.56 (3.86-28.86) 9.60 (3.44-26.82) 
     
Seizures during preceding year  
 No (ref) 26 577 1 1 
Yes, but not GTCS   12 290 0.97 (0.48-1.96) 1.15 (0.54-2.46) 
GTCS   217 280 22.70 (13.72-37.55) 26.81 (14.86-48.38) 
     
 
0 (ref) 38 865 1 1 
1-3 106 150 19.51 (11.94-31.88) 22.14 (12.74-38.46) 
4-10 50 42 28.24 (15.36-51.92) 31.87 (15.95-63.67) 
>10 61 88 26.38 (14.62-47.61) 29.70 (15.04-58.63) 
     
 
No (ref) 63 711 1 1 
Yes, non-GTCS 2 102 0.23 (0.06-0.98) 0.27 (0.06-1.15) 
Yes, GTCS 190 335 8.44 (5.91-12.04) 9.04 (6.08-13.45) 
     
 
No (ref) 145 1049 1 1 
Yes 110 99 12.98 (8.61-19.56) 15.31 (9.57-24.47) 
     
 
Epilepsy surgery 
 
No (ref) 242  1098  1 1 
yes 13  50  1.27 (0.66-2.44) 0.77 (0.31-1.92) 
     
VNS     
No (ref) 244  1098  1 1 
yes 11  50  1.29 (0.65-2.57) 0.41 (0.17-0.98) 
     
Living conditions     
Sharing household and 
bedroom (ref) 
32 391 1 1 
Sharing household but 
not bedroom 
49  398 2.43 (1.36-4.32) 2.28 (1.14-4.58) 
Not sharing household 174  359e  6.11 (4.04-9.22) 5.01 (2.93-8.57) 
     
 
a Adjusted for age and sex (matching variable) 
b Adjusted for age, sex, GTCS frequency and nocturnal GTCS last year of observation (except in the analyses of 
seizures), living conditions and AEDs 
 
 
 
 
 
5.4 Pharmacological treatment and SUDEP risk (paper IV)   
No AED, neither as monotherapy or in polytherapy combination increased the risk for 
SUDEP (figure 7). Using no AED treatment as reference, polytherapy, especially taking three 
or more AEDs was associated with a 69% reduced SUDEP risk after adjusting for GTCS 
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frequency and other covariates (table 5). Out of the seven most commonly used AEDs, only 
levetiracetam was associated with a significantly lower SUDEP risk when compared to no 
AED treatment (OR 0.10, 95% CI 0.03-0.61). Lamotrigine, valproic acid and levetiracetam 
were associated with a significantly reduced risk when used as part of a polytherapy (figure 
7). SUDEP risk in relation to lamotrigine use was analyzed separately for females and there 
was no indication of excess risk neither when used as mono- nor polytherapy. 
 
Figure 7. Forest plot showing odds ratio (OR) and 95% confidence interval (CI) of SUDEP 
in relation to specific antiepileptic drugs (AEDs) as mono and polytherapy (reference is 
individuals not on that AED, based on model 3). 
 
When analyzing adherence, the analysis was restricted to individuals for which medical 
records stated that AEDs were prescribed during the last year of observation. Using 0-90 days 
as reference, individuals with 181-365 days since last dispensing had an OR of 2.96 (95% CI 
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0.46-18.86) when adjusting for GTCS among other covariates. While when not adjusting for 
GTCS in the same group, the risk became more pronounced and significant, OR 3.41 (95% 
CI 1.05-11.09). Similarly, having non-adherence mentioned in the medical record was 
associated with an OR of 2.75 (95% CI 1.58-4.78). Use of statins was associated with a 
reduced risk of SUDEP (OR 0.34, 95% CI 0.11-0.99) but we did not observe a reduced risk 
with SSRIs or other antidepressants, or beta blockers, nor an increased risk with neuroleptics.  
 
Table 5. Odds ratio (OR) and 95% confidence interval (CI) of SUDEP in relation to anti-
epileptic drugs (AED), time since last dispensed AED and non-adherence noted in medical 
records 
Table 5. Odds ratio (OR) and 95% confidence interval (CI) of SUDEP in relation to anti-
epileptic drugs, time since last dispensed antiepilepti  drug and non-adherence as noted in 
medical records. 
 
a No AED dispensed within 90 days of death or index date. b Only one AED dispensed within 90 days of death or 
index date. c Two or more AEDs dispensed within 90 days of death or index date. d Model 1 is adjusted for 
matching variables (sex and calendar time) and age.  e Model 2 is adjusted for same variables as Model 1 
together with duration and type of epilepsy, living conditions (sharing bedroom), intellectual disability, 
substance abuse, alcohol dependence, education level, f Model 3 is adjusted for same variables as Model 2 
together with history of GTCS, GTCS frequency last year of observation and nocturnal GTCS last year of 
observation. g Seven most common monotherapies. h Restricted to individuals prescribed AEDs according to 
patient records. 
 
  
No. 
Cases  
 
No.  
Controls  
Model 1d 
 
OR (95% CI) 
Model 2e 
 
OR (95% CI) 
Model 3f 
 
OR (95% CI) 
 
      
AED therapy      
No AEDsa 46 265 1 1 1 
Monotherapyb  113 483 1.15 (0.79-1.69) 1.03 (0.67-1.57) 0.79 (0.44-1.41) 
Polytherapyc  96 400 1.24 (0.83-1.84) 0.90 (0.57-1.42) 0.48 (0.26-0.90) 
2 AEDS  65 272 1.22 (0.80-1.87) 0.94 (0.58-1.51) 0.59 (0.31-1.12) 
≥3 AEDS  31 128 1.27 (0.76-2.12) 0.81 (0.45-1.48) 0.31 (0.14-0.67) 
       
      
Time since last dispensed AEDh     
0-90 days  199 871 1 1 1 
91-180 days  16 85 0.85 (0.48-1.49) 1.13 (0.61-2.08) 1.20 (0.50-2.87) 
181-365 days  6 15 1.99 (0.72-5.51) 3.41 (1.05-11.09) 2.96 (0.46-18.89) 
>365 days  14 33 1.92 (0.99-3.71)  2.42 (1.14-5.14)  2.25 (0.73-6.90) 
      
Non-adherence mentioned in medical record    
No 173 886 1 1 1 
Yes 62 118 2.47 (1.73-3.54) 2.56 (1.70-3.84) 2.75 (1.58-4.78) 
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6 DISCUSSION 
6.1 MAIN FINDINGS  
The purpose of this study was to examine the incidence, circumstances and risk factors for 
SUDEP in Sweden. Our results support the previous notion that SUDEP is a major cause of 
death in epilepsy patients, since our data suggest that approximately 100 patients die every 
year in Sweden due to SUDEP. Furthermore, SUDEP accounts for one third of deaths in 
children with epilepsy and one fifth of deaths among young adults with epilepsy. Since the 
majority died at home in bed, at night with indications of a previous GTCS, SUDEP can be 
considered as an event related to night time GTCS. We found no excess risk of SUDEP 
among individuals experiencing non-GTCS only, which has important clinical implications. 
GTCS and lack of supervision were the main risk factors. Compared to an epilepsy patient 
that shares bedroom and is free from GTCS, an individual with more than four GTCS a year 
who sleeps alone has an 82-fold increased SUDEP risk. Moreover, our results suggest that up 
to 69% of SUDEP cases could be prevented in individuals with GTCS who live alone, if they 
were made free from GTCS or did not sleep alone. An interesting finding was that 
polytherapy, in particular with three or more AEDs, was associated with a substantially 
reduced SUDEP risk, this notably after adjusting for GTCS. Regarding monotherapy, the 
lowest SUDEP risk was seen among users of levetiracetam and an increased SUDEP risk was 
observed among those considered to be non-adherent. Statins were associated with a reduced 
SUDEP risk whereas we found no support for a protective effect of SSRIs.  
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6.2 RESULTS IN RELATION TO PREVIOUS RESEARCH 
6.2.1 The incidence of SUDEP 
Despite some differences in methodology, our observed incidence of 1.20 (0.93-1.52) per 
1000 person-years is very similar to the rate of 1.16 (0.95-1.36) reported in a pooled analysis 
(Thurman et al., 2014) of three high quality population-based studies (Leestma et al., 1989; 
Langan et al., 1998; Opeskin and Berkovic, 2003). However, our findings of incidence rates 
differ markedly from the incidence of 0.2-0.43 per 1000 that has been reported in children in 
the past (Donner et al., 2001; Weber et al., 2005; Hesdorffer et al., 2011; Berg et al., 2013; 
Thurman et al., 2014). Since then, a population-based study in Canada, has confirmed our 
findings on the incidence of SUDEP in children (Keller et al., 2018). Over a period of two 
years (2014-2015), the researchers found 17 pediatric SUDEP cases in the state of Ontario, 
resulting in an incidence of 1.11 (0.63-1.79 per 1000 person-years which is exactly as ours 
(figure 5).  
 
We found a higher SUDEP risk in the older age group than previously thought. Our results 
are in agreement with the opinion that the undercount of SUDEP might be great in older age 
groups (Thurman et al., 2014; Devinsky et al., 2016b). The higher occurrence of competing 
causes of death, lower autopsy rates among older persons, less documentation to be found 
regarding the circumstances of sudden death in the older age, all contribute to this under-
ascertainment. This highlights the difficulties in obtaining a reliable assement of the SUDEP 
risk in older people. 
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6.2.2 Circumstances of SUDEP 
Our results show that most SUDEP victims live alone or do not share a bedroom. This is line 
with a previous case-control study showing lack of night-time supervision as an important 
risk factor (Langan et al., 2005) and another study were SUDEP only occurred when children 
with severe epilepsy, enrolled at a special residential school, were on leave from the 
institution and did not have their regular supervision (Nashef et al., 1995).  
 
Our results support further that SUDEP is a GTCS related event. In the MORTEMUS study 
(Ryvlin et al., 2013), all fatalities were preceded by a GTCS. In our study, all witnessed 
preceding seizures were GTCS. We were also able to compare definite SUDEP deaths to 
autopsied non-SUDEP deaths, when known, a GTCS preceded 21% among the witnessed 
deaths, while this was the case in 95% among the definite SUDEP cases. There were, 
however, five witnessed SUDEP cases in our series that were not preceded by a seizure. 
Although rare, this has been reported before (Lhatoo et al., 2016). This could imply at least 
two things. Firstly, that SUDEP can have a heterogeneous pathophysiology (Tomson et al., 
2008). Secondly, sudden unexpected deaths occur in the general population, even though it is 
24 times less common than in the epilepsy population. Hence, some sudden deaths in the 
epilepsy population may have no connection with the comorbid epilepsy.  
 
Regarding seasonality of SUDEP, we did not observe a higher incidence during the winter 
months as in sudden cardiac death and Sudden Infant Death Syndrome (SIDS) (Douglas et 
al., 1998; Arntz et al., 2000; Gerber et al., 2006). This is in line with a SUDEP study from the 
UK which relied on death certificates only (Bell et al., 2010). Neither did we find an 
increased occurrence during morning hours or Mondays as in sudden cardiac deaths (SCD) 
(Arntz et al., 2000). As reported before (Lear-Kaul et al., 2005; Hitiris et al., 2007; Zhuo et 
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al., 2012; Clark and Riney, 2016) we found a clear preponderance for SUDEP to occur at 
night. Thus, SUDEP is predominately a GTCS and a night time related event and differs in 
many aspects from SIDS and SCD.  
 
In the majority of SUDEP cases where body position was documented, they were found in 
the prone position. This is line with previous studies (Earnest et al., 1992; Kloster and 
Engelskjon, 1999; Opeskin and Berkovic, 2003; Liebenthal et al., 2015). Those who died at 
night were also more often found in the prone position than deaths occurring at other times 
and in our reference group of autopsied non-SUDEP the prone position was much less 
common than in the definite SUDEP group. The MORTEMUS study showed that many of 
the victims did not sleep in the prone position but shifted to that position during the seizure. 
Therefore, it is unlikely that campaigns promoting epilepsy patients to sleep on their back 
would be of any help. With this said it is possible that the position during a seizure can have a 
bearing on the final outcome and that simple interventions such as shifting the patient 
position and stimulation after the seizure could reduce the SUDEP risk (Nashef et al., 1995; 
Langan et al., 2005). This is still unproven but the use of a listening devise or regular checks 
during the night or shearing a room with an individual capable of giving assistance were 
associated with a markedly decreased risk SUDEP risk in one case-control study (Langan et 
al., 2005). There is a steady development in seizure alert alarms which might reduce SUDEP 
risk in the future (Ryvlin et al., 2018a). At the same time someone needs to be close by, 
respond and know how to reposition the patient, ensure that airways are not obstructed and 
possibly provide oxygen or suctioning (Devinsky et al., 2016a). This imposes challenges 
since the majority of Swedish SUDEP victims live alone. 
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6.2.3 Clinical risk factors and SUDEP risk 
Our results confirm the main conclusion of the pooled analysis of four case-control studies 
(Hesdorffer et al., 2011) and the recent systematic review (Harden et al., 2017) that the 
presence and frequency of GTCS is by far the strongest risk factor for SUDEP. This applied 
also to nocturnal GTCS. In line with the previous pooled analysis of case-control-studies 
(Hesdorffer et al., 2011) we saw an incremental risk increase from no seizures up to 4-10 
GTCS.  
 
Previous studies have focused on GTCS or seizures as a whole but have not systematically 
analyzed non-GTCS. Therefore, is it an important result, that no increased SUDEP risk was 
seen in patients with only non-GTCS. This applied also to nocturnal non-GTCS. This has not 
been analyzed before to our knowledge (Nilsson et al., 1999; Walczak et al., 2001; Langan et 
al., 2005; Hitiris et al., 2007; Hesdorffer et al., 2011; Harden et al., 2017). This information is 
useful when counseling the individual patient. Complete seizure freedom cannot be expected 
in all patients, but it appears that much can be gained if focal seizures can be contained and 
prevented from evolving to bilateral tonic-clonic seizures.  
 
VNS treatment was associated with a 59% risk reduction. These are interesting findings but 
due to the small numbers they should be interpreted with caution. The results aiming at 
assessing the effects of VNS on SUDEP risk have been somewhat conflicting (Annegers et 
al., 2000; Granbichler et al., 2015). This was addressed in a retrospective analysis of a large 
database of 40,443 patients with VNS therapy up ten years after implantation (Ryvlin et al., 
2018b). In this cohort, the SUDEP risk was 25% lower during years 3-10 compared to the 
first two years. Despite large numbers, these findings need also to be interpreted with caution 
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due to the lack of a control group and the tendency for SUDEP incidence to decrease over 
time, as shown in a Swedish study (Tomson et al., 2018).    
 
We observed as previous studies (Hesdorffer et al., 2011) that substance abuse and alcohol 
dependence, both which can lower the seizure threshold, increased the risk and should be 
taken into consideration when counseling the patient. Once we adjusted for GTCS frequency 
a number of formerly proposed risk factors (Nilsson et al., 1999; Walczak et al., 2001; 
Langan et al., 2005; Tomson et al., 2016), examples being age at onset, comorbid mental 
health disorders and use of antipsychotic drugs, were not associated with SUDEP. 
Furthermore, no increased risk was observed in those with a history of heart disease 
(arrythmias, heart failure, cardiomyopathy or ischemic heart disease) or chronic lower 
respiratory diseases or other neurological disorders.  
 
In line with a previous report (Langan et al., 2005) of a protective effect of nighttime 
supervision (sharing a bedroom with someone capable of giving assistance or regular checks 
throughout the night or use of listening devices) and another study reporting SUDEP more 
common in an epilepsy center with less supervison at night (van der Lende et al., 2018), we 
saw a substantially greater SUDEP risk for those living alone, especially those not sharing a 
bedroom.  
 
With interaction analysis we were able to demonstrate a supra-additive increase in SUDEP 
for those who have GTCS and sleep alone. Up to 69% of these deaths could possibly be 
prevented by removal of one of these risk factors. Sharing a room with someone is of course 
not always possible or desired and this highlights the dilemma between the wish to reduce 
SUDEP risk and the desire to live an independent life.  
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6.2.4 Pharmacological treatment, adherence and SUDEP risk 
Our results on polytherapy are compatible with observations in a previous meta-analysis of 
placebo-controlled randomized trials investigating adjunctive AED treatment of pharmaco-
resistant epilepsy (Ryvlin et al., 2011). In this meta-analysis, identifying 20 SUDEP cases (18 
definite or probable), SUDEP was significantly less frequent in the group randomized to add-
on with an AED at a presumed efficacious dose than in the add-on placebo group (Ryvlin et 
al., 2011). In contrast to our present study, data on seizure control in relation to SUDEP 
occurrence were not available in this meta-analysis. Our results that polytherapy reduces the 
risk for SUDEP together with Ryvlin’s observations should encourage physicians to consider 
adding an AED in patients experiencing GTCS despite optimised monotherapy. Polytherapy 
was associated with reduced SUDEP risk even after adjustment for GTCS frequency. How 
polytherapy can reduce the risk for SUDEP beyond its effect on GTCS frequency is, 
however, unknown. One possibility is that polytherapy decreases the severity of the GTC 
with less impact on e.g. ascending and descending arousal systems. This could subsequently 
lead to less unresponsiveness and respiratory depression and reduced SUDEP risk.  
 
No AED was associated with an increased SUDEP risk, neither before nor after adjusting for 
covariates. The results of the less frequently used AEDs, levetiracetam, oxcarbazepine, and 
topiramate, need to be interpreted cautiously given the smaller numbers and the 
corresponding wider confidence intervals. Interestingly, out of the different AEDs used in 
monotheraphy, the lowest risk was seen in users of levetiracetam, with an OR of 0.10. To our 
knowledge this finding has not been reported before. Levetiracetam has a mode of action 
different from other AEDs. Whether this relates to a particularly beneficial impact on SUDEP 
risk, remains to be explored. 
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Contrary to some other studies, we did not find an increased SUDEP risk in individuals 
taking carbamazepine (Timmings, 1993; Langan et al., 2005). One previous small case-
control study has suggested an increased SUDEP risk specifically among female patients 
treated with lamotrigine (Aurlien et al., 2007), an observation that was not confirmed in the 
present study. 
 
Compared to adherence, non-adherence was associated with a more than a threefold higher 
mortality in a retrospective cohort study from the US, where Medicaid claims data were used 
to evaluate adherence to treatment in epilepsy patients with AED prescriptions (Faught et al., 
2008).  A study from the UK, using similar methods as we, also found non-adherence to be 
associated with an increased mortality (Risdale et al., 2011). In both these studies the 
investigators analysed all-cause mortality and not SUDEP specifically. In our study, using 
physicians’ mentioning of non-adherence in medical records yielded a threefold increased 
risk of SUDEP. We observed the same tendency when time since last dispensed AED 
exceeded 180 days in model 2, supporting the role of non-adherence as a risk factor for 
SUDEP. The high risk associated with GTCS and the risks associated with poor adherence 
should prompt physicians and patients to take measures to improve seizure control and 
facilitate adherence. 
 
As mentioned before, data from people with epilepsy suggest that SSRIs are associated with 
reduced peri-ictal oxygen desaturation in focal seizures, but not in GTCS (Bateman et al., 
2010). Moreover, pre-treatment with fluoxetine, an SSRI antidepressant prevented the 
postictal respiratory arrest and SUDEP in an animal seizure model (Tupal and Faingold, 
2006). We did, however, not find a reduced risk of SUDEP with use of SSRI or other 
antidepressants. This is in line with a study which did not find evidence that SSRIs protected 
 50 
against all-cause mortality in a large population-based cohort study of people with epilepsy 
(Josephson et al., 2017).  Pharmacological treatment (beta blockers and statins) has been tried 
successfully in prevention of sudden cardiac death in patients with coronary artery disease, 
post myocardial infarction, structural heart disease and congestive heart failure (Arshad et al., 
2008). Atypical and typical antipsychotics have been shown to increase mortality, including 
sudden cardiac death (Murray-Thomas et al., 2013). However, SUDEP risk has not been 
assessed in relation to beta blockers, statins, or neuroleptics before. We did neither observe an 
increased nor reduced SUDEP risk with concomitant use of neuroleptics or beta blockers, 
however, statin use was associated with a 66% reduced SUDEP risk even after adjusting for 
GTCS frequency. An association has been found between the use of statins and a reduced risk 
of developing epilepsy (Etminan et al., 2010) and intake of statins has been associated with 
reduced mortality in status epilepticus (Sierra-Marcos et al., 2015). There are also studies 
reporting statins to reduce the risk of sudden cardiac death (Beri et al., 2010), but ours is the 
first study to indicate a reduction in the risk of SUDEP.  
 
6.3 METHODOLOGICAL ASPECTS  
6.3.1 Strengths of the studies 
The main strengths of our studies are their size and that they are nation- and population-
based. Considering that the total Swedish population in 2002 was 8.925 million, and an 
estimated epilepsy prevalence of 0.6%, the 78,524 individuals identified in the SNPR during 
1998–2005 most likely represent the vast majority of inhabitants with epilepsy. A further 
strength is the fact that the controls came from the same population as the cases, and that we 
were able to attain records for 97% of the 1275 potential controls and that we reviewed all 
deaths for one year (2008), with meticulous assessment of all relevant documentation for all 
potential SUDEP cases. Additionally, the validity of the epilepsy diagnosis was ascertained 
with chart review, and those not meeting the epilepsy criteria were excluded. It is therefore 
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likely that the results are representative for other countries with similar socioeconomic 
standards and healthcare systems. Another strength was that we used data from the Swedish 
Prescribed Drug Register which covers all prescriptions dispensed in pharmacies in Sweden, 
which is likely to be more accurate in terms of what the patient is realistically taking than 
information from patient records or prescription data from registries, as a measure of 
adherence. To our knowledge this methodology in combining extensive records review and 
registers has not been applied to this extent before in evaluating SUDEP risk.  
 
6.3.2 Limitations of the studies 
As described above, we assume that the majority of individuals with epilepsy between 1998-
2005 were included in our study population. However, this is not known for certain since 
patients followed by family physicians who did not seek hospital during the eight-year period 
will not be included in the study population. It is conceivable that some milder cases of 
epilepsy were missed. We might therefore have underestimated the denominator somewhat 
and possibly overestimated the incidence of SUDEP, since the frequency of SUDEP is likely 
to be lower among people with milder forms of epilepsy. Since our review of medical charts, 
suggests that roughly 10% of the individuals in the study population do not have epilepsy, 
this would on the other hand have contributed to an overestimation of the denominator. 
Furthermore, our study was performed on a prevalent epilepsy population and did not 
specifically follow incident cases from their epilepsy onset. Some caution is therefore 
justified in attempts to apply our results on newly diagnosed epilepsies.  
 
Misclassification of SUDEP is possible, not the least since it is a diagnosis of exclusion. 
Pitfalls include for example the possibility of patients having died from an unwitnessed status 
epilepticus. Furthermore, around half of our 329 SUDEP cases were not autopsied. This is the 
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reason we primarily included only definite and probable cases in the case-control study. We 
found a high concordance between the older classification (Annegers, 1997) and the more 
recent (Nashef et al., 2012).  
 
Among the weaknesses are that the authors extracting information were not blinded to the 
outcome, and aware of previous reports on SUDEP risk factors, which may introduce bias. 
Furthermore, patient records have their inherent limitations, but we had relatively extensive 
records for both cases and controls and information was collected identically using a 
standardized protocol for both cases and controls. The registries used also have their 
limitations. Even though we found the ICD code for epilepsy to have a validity of 90% this 
does not necessary hold for other diagnoses used in the study.  
 
With respect to living conditions, information was somewhat more extensive on the cases 
than controls due to additional information collected in conjunction with their death. With 
this said, information on living conditions was absent in only a small fraction of controls and 
should not have a major impact on our results. In reference to circumstances of death, another 
potential bias could be that it is easier for a witness to detect a GTCS than a non-GTCS and 
the latter can therefore go unnoticed.   
 
Our definitions of being on an AED and adherent (AED dispensed within 90 days of death or 
index date) could be too strict. It is conceivably that patients had accumulated medications 
over time and have not dispensed AEDs or other medications within 90 days of death or 
index date without being non-adherent. This could possibly underestimate SUDEP risk in 
association to non-adherence. Additionally, dispensing medication does not guarantee intake. 
Furthermore, the prescription registry does not include those individuals living in an 
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institution which are for example common for chronic epilepsy patients in other countries. 
Since Sweden does not have such institutions and that very few cases or controls were 
admitted to hospital in the months leading up to death or index datum which could affect 
dispensing of drugs, it should not affect our results.   
 
Our study was observational and therefore we cannot rule out confounding. This is of 
concern in paper III and IV where we aimed to identify risk factors for SUDEP. Even though 
we could adjust for a wide range of potential confounders, more than in any previous SUDEP 
study, there could be unknown confounders or residual confounding contributing to the 
observed associations. Moreover, some of the risk factors studied could be mediators, i.e. in 
the causal chain between the exposure and outcome. Furthermore, despite this being the 
largest SUDEP study until now, some analyses, e.g. those addressing individual AEDs and 
epilepsy surgery were hampered by small numbers, and wide confidence intervals. These 
findings should consequently be interpreted with caution.  
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7 CONCLUSION 
More than one in every thousand epilepsy patients dies every year due to SUDEP and around 
100 individuals in Sweden every year. SUDEP does not predominately affect young adults as 
thought before and it is evident that neither death certificates nor cause-of-death registries can 
be used for reliable monitoring of SUDEP incidence over time. GTCS, here including focal to 
bilateral as well as generalized tonic-clonic seizures, are indisputably a decisive risk factor for 
SUDEP for the following reasons; We found no increase in those with non-GTCS seizures 
alone; All seizures in conjunction with witnessed SUDEPs were GTCS and the majority of 
unwitnessed cases had indirect signs of a previous GTCS. We observed a gradual risk 
increase from having a history of GTCS, through the presence of GTCS and increased 
frequency of GTCS during the last year of observation. SUDEP is also obviously a night time 
and sleep related event considering that the majority died in bed at night. What makes 
SUDEP more susceptible to occur at night is not fully apparent. It could be the lack of 
supervision as indicated by our finding that not sharing a bedroom increased the SUDEP risk. 
Even though GTCS is a stronger risk factor, these two risk factors together evidently have a 
magnifying effect on each other since those with ≥4 GTCS who lived alone had an 82-fold 
increased risk for SUDEP. On the positive side, our findings indicate that 69% of SUDEPs 
could potentially be prevented if patients were free from GTCS or did not sleep alone. This 
and the protective effect of polytherapy has not been demonstrated before. Our results 
provide support for the importance of medication adherence and intensified AED treatment. 
The available evidence suggests that physicians may want to consider AED polytherapy more 
pro-actively for patients with poorly controlled GTCS. Finally, our findings did not support 
the previously suggested preventive role of SSRIs, while we found indications that statins 
might have a protective effect which needs to be researched further.    
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8 FUTURE PERSPECTIVES 
Even though knowledge on the incidence, circumstances and risk factors in SUDEP has 
improved with this study, a number of challenges remain and should be considered for future 
studies. Regarding seizure control and SUDEP risk, studies are needed that differentiate 
between focal to bilateral tonic-clonic seizures and generalized tonic-clonic seizures. Studies 
are also needed that aim to clarify by what mechanisms AEDs reduce SUDEP risks apart 
from reducing frequency of GTCS. Considering the importance of living conditions, it would 
be interesting to compare SUDEP incidence in communities where living condition are 
different, e.g. comparing the SUDEP incidence in Sweden with that in societies where living 
alone is less prevalent and where people with severe epilepsy are more likely to live in 
residential care. 
 
Independent studies are needed to confirm or refute the observed differences between AEDs 
and the apparent protective effect of statins. Future intervention studies aiming at assessing 
potential preventive measures could consider in addition to pharmacological interventions, 
systematic efforts to enhance adherence, effectiveness of different seizure detection alarms 
and other monitoring systems. Further refinement of individual SUDEP risk estimates would 
be of value both for patient counselling and for the selection of patients for intervention 
studies. Methods need to be developed that permit surveillance of SUDEP incidence over 
time in large populations and that ideally are applicable across countries. This would be 
important from a public health perspective, but also for future intervention studies. 
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